Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,853,639 | $2,049,438 | $1,353,394 | $2,916,767 |
| - Cash | $594,350 | $391,565 | $549,912 | $285,116 |
| + Debt | $108,492 | $50,672 | $51,005 | $11,478 |
| Enterprise Value | $1,367,781 | $1,708,545 | $854,487 | $2,643,129 |
| Revenue | $58,839 | $43,876 | $39,681 | $10,000 |
| % Growth | 34.1% | 10.6% | 296.8% | – |
| Gross Profit | $13,601 | $1,289 | -$8,594 | $10,000 |
| % Margin | 23.1% | 2.9% | -21.7% | 100% |
| EBITDA | -$426,722 | -$307,629 | -$227,665 | -$175,122 |
| % Margin | -725.2% | -701.1% | -573.7% | -1,751.2% |
| Net Income | -$463,661 | -$328,066 | -$239,476 | -$186,479 |
| % Margin | -788% | -747.7% | -603.5% | -1,864.8% |
| EPS Diluted | -1.69 | -1.58 | -1.36 | -1.05 |
| % Growth | -7% | -16.2% | -29.5% | – |
| Operating Cash Flow | -$359,174 | -$287,780 | -$83,524 | -$158,614 |
| Capital Expenditures | -$13,695 | -$11,955 | -$37,359 | -$39,798 |
| Free Cash Flow | -$372,869 | -$300,332 | -$120,883 | -$198,412 |